Table 2 Reported prevalence of Anti-HBc, HBV DNA and OBI in HBsAg Negative blood donors based on some published studies in Iran
Reference | City | Number of donors (HBsAg-) | Anti-HBc+ n (%) | HBV DNA+/Anti-HBc+ n (%) | OBI n (%) |
|---|---|---|---|---|---|
Sofian et al. [12] | Arak | 531 | 11(2.1 %) | 0/11 (0 %) | 0 |
Shahabi et al. a | Mashhad | 5059 | 432(8.5 %) | 0/60 (0 %) | 0 |
AminiKafi-abad et al. [13] | Tehran | 2000 | 230 (11.5) | 0/230 (0 %) | 0 |
Khamesipour et al. [14] | Rasht | 2041 | 78 (3.8 %) | 1/78 (1.3 %) | 1 (0.05 %) |
Pourazar et al. [15] | Isfahan | 545 | 43 (8 %) | 5/43 (11.62 %) | 5 (0.92 %) |
Behbahani et al. [16] | Shiraz | 2000 | 131 (6.55 %) | 16/131 (12.2 %) | 16 (0.8 %) |
Arababadi et al. [17] a | Rafsanjan | 3700 | 352 (9.51 %) | 57/352 (16.1 %) | 57 (1.54 %) |
Jafarzadeh et al. [18] | Rafsanjan | 270 | 14 (5.18 %) | 4/14 (28.57 %) | 4 (1.48 %) |
Delavari et al. [19] | Kerman | 1525 | 121 (8 %) | 36/121 (29.7 %) | 36 (2.36 %) |
Vaezjalali et al. [20] | Tehran | 1000 | 80 (8 %) | 40/80 (50 %) | 40 (4 %) |
Alizadeh et al. [21] | Tehran | 5000 | 499 (9.8 %) | 2/499 (0.4 %) | 2 (0.04 %) |
Total | – | 23,671 | 1991 (8.4 %) | 161 (9.9 %) | 161 (0.7 %) |